114 related articles for article (PubMed ID: 16535881)
1. [Sweden should follow Norway and introduce vaccination against pneumococci].
Schulman S; Sveger T
Lakartidningen; 2006 Feb 15-21; 103(7):480. PubMed ID: 16535881
[No Abstract] [Full Text] [Related]
2. [Time to vaccinate infants and small children against pneumococci].
Silfverdal SA; Gothefors L
Lakartidningen; 2006 Feb 15-21; 103(7):477-8. PubMed ID: 16535879
[No Abstract] [Full Text] [Related]
3. Pneumococcal vaccination: yes or no.
Sharda KB
Indian Pediatr; 2008 Jun; 45(6):519. PubMed ID: 18599950
[No Abstract] [Full Text] [Related]
4. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
6. [Survey on vaccination strategies used in different Italian Regions, for the 7-valent conjugate pneumococcal, meningococcal C and varicella vaccines].
D'Ancona F; Alfonsi V; Ciofi degli Atti ML
Ig Sanita Pubbl; 2006; 62(5):483-92. PubMed ID: 17206224
[TBL] [Abstract][Full Text] [Related]
7. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
[TBL] [Abstract][Full Text] [Related]
8. Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. An Advisory Committee Statement (ACS).
National Advisory Committee on Immunization (NACI)
Can Commun Dis Rep; 2006 May; 32(ACS-4):1-6. PubMed ID: 16718922
[No Abstract] [Full Text] [Related]
9. US study suggests universal vaccination of children with pneumococcal conjugate vaccine is beneficial for adults.
Doroshenko A
Euro Surveill; 2005 Nov; 10(11):E051124.4. PubMed ID: 16794287
[No Abstract] [Full Text] [Related]
10. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
[TBL] [Abstract][Full Text] [Related]
11. [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].
de Vries M; Dankert J; Ruijs H; Timen A; de Greeff S; de Melker H
Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1562-3. PubMed ID: 12212505
[No Abstract] [Full Text] [Related]
12. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
Pletz MW; Maus U; Krug N; Welte T; Lode H
Int J Antimicrob Agents; 2008 Sep; 32(3):199-206. PubMed ID: 18378430
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
14. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media.
Cohen R; Levy C; de La Rocque F; Gelbert N; Wollner A; Fritzell B; Bonnet E; Tetelboum R; Varon E
Pediatr Infect Dis J; 2006 Nov; 25(11):1001-7. PubMed ID: 17072121
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children.
Sánchez-Tatay D; Arroyo LA; Tarragó D; Lirola MJ; Porras A; Fenoll A; Hausdorff WP; Brueggemann AB; Obando I
Clin Microbiol Infect; 2008 Aug; 14(8):797-801. PubMed ID: 18727804
[TBL] [Abstract][Full Text] [Related]
16. [Acute epiglottitis now affecting adults is mostly caused by pneumococci. Important to observe the incidence when considering future vaccination strategy].
Isakson M; Hugosson S
Lakartidningen; 2007 Nov 21-27; 104(47):3531-3. PubMed ID: 18203585
[No Abstract] [Full Text] [Related]
17. Prevnar--will it be the next vaccine success story?
Fiechtner HB
S D J Med; 2003 Sep; 56(9):377-8. PubMed ID: 14524137
[No Abstract] [Full Text] [Related]
18. Prevenar vaccination: review of the global data, 2006.
Center KJ
Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Lucioni C; Mazzi S
Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601
[No Abstract] [Full Text] [Related]
20. [Vaccination requirements in patients with gastroenterological diseases (hepatitis A and B, pneumococcal and meningococcal vaccination)].
Weinke T; Güthoff W; Jahn HU
Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S104-6. PubMed ID: 15368185
[No Abstract] [Full Text] [Related]
[Next] [New Search]
